According to industry reports, the pharmaceutical sector accounts for as much as 4.4% of emissions worldwide, and if no action is taken, its greenhouse gas (GHG) emissions could triple by 2050. Interestingly, compared to Scope 1 and Scope 2 emissions, Scope 3 emissions comprise most of the pharma sector’s carbon footprint.

As the industry confronts challenges of substantial environmental impact from Scope 3 emissions, collaboration between drug makers and their CDMO partners is becoming increasingly critical. Already, there has been a distinct shift, with sustainability becoming an integral part of pharma business strategy instead of just “good to have”. An increasing number of pharma companies are also prioritizing sustainability when discussing projects with their CDMO partners. CDMOs, in turn, have been quick to embrace sustainability and pursue net-zero carbon emissions driven by regulatory pressures, the need to fit in with the customer’s strategy, and help customers cut costs.

This article explores the “sustainability metrics” that are becoming more important when selecting a CMO/CDMO, even as technology, track record, capacity, and cost remain the top criteria for selecting an outsourcing partner.

To drive your sustainability agenda forward, contact our experts.